UK markets closed

Bio-Rad Laboratories, Inc. (BIO-B)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
769.89-0.00 (-0.00%)
At close: 12:19PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 522.21B
Enterprise value 321.10B
Trailing P/E 3.49
Forward P/E 150.51
PEG ratio (5-yr expected) 13.63
Price/sales (ttm)7.80
Price/book (mrq)1.50
Enterprise value/revenue 37.08
Enterprise value/EBITDA 72.43

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 342.45%
S&P500 52-week change 326.87%
52-week high 3818.60
52-week low 3540.45
50-day moving average 3747.93
200-day moving average 3673.87

Share statistics

Avg vol (3-month) 3100
Avg vol (10-day) 320
Shares outstanding 55.08M
Implied shares outstanding 629.92M
Float 821.44M
% held by insiders 1106.61%
% held by institutions 12.17%
Shares short (14 Nov 2021) 47
Short ratio (14 Nov 2021) 40.06
Short % of float (14 Nov 2021) 40.00%
Short % of shares outstanding (14 Nov 2021) 40.00%
Shares short (prior month 14 Oct 2021) 43

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 307 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 223.47%
Operating margin (ttm)20.89%

Management effectiveness

Return on assets (ttm)2.43%
Return on equity (ttm)55.13%

Income statement

Revenue (ttm)2.98B
Revenue per share (ttm)99.96
Quarterly revenue growth (yoy)15.40%
Gross profit (ttm)1.44B
EBITDA 758.89M
Net income avi to common (ttm)6.66B
Diluted EPS (ttm)220.48
Quarterly earnings growth (yoy)198.70%

Balance sheet

Total cash (mrq)1.34B
Total cash per share (mrq)44.69
Total debt (mrq)225.26M
Total debt/equity (mrq)1.47
Current ratio (mrq)3.80
Book value per share (mrq)512.48

Cash flow statement

Operating cash flow (ttm)783.33M
Levered free cash flow (ttm)622.38M